Results 241 to 250 of about 368,214 (310)

Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors

Journal of clinical pharmacology, 2018
Although current quetiapine labeling recommends that its dosage should be lowered 6‐fold when coadministered with strong cytochrome P450 (CYP)3A inhibitors, a reported case of coma in a patient receiving quetiapine with lopinavir and ritonavir prompted ...
M. Sampson, Kelly Cao, Paula Gish, K.Mun Hyon, P. Mishra, William Tauber, P. Zhao, Esther H Zhou, Islam R Younis   +8 more
semanticscholar   +1 more source

Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor

Blood, 2000
AbstractThe malignant Reed-Sternberg cell of Hodgkin disease is an aberrant B cell that persists in an immunolgically mediated inflammatory infiltrate. Despite its nonproductive immunoglobulin genes, the Reed-Sternberg cell avoids the usual apoptotic fate of defective immune cells through an unknown mechanism. A likely candidate is the surface receptor,
Christina M. Annunziata, Yassamin J. Safiran, Steven G. Irving, Usha N. Kasid, Jeffrey Cossman   +4 more
openaire   +1 more source

Optimal therapies of a virus replication model with pharmacological delays based on reverse transcriptase inhibitors and protease inhibitors

Journal of Physics A: Mathematical and Theoretical, 2017
Summary: A short delay in the pharmacological effect on account of the time required for drug absorption, distribution, and penetration into target cells after application of any anti-viral drug, is defined by the pharmacological delay [\textit{A. V. Herz} et al., ``Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
Pei, Yongzhen, Li, Changguo, Liang, Xiyin   +2 more
openaire   +2 more sources

Proteases and protease inhibitors in saliva of hard ticks: Biological role and pharmacological potential

Hard ticks (family Ixodidae) are significant vectors of pathogens affecting humans and animals. This review explores the composition of tick saliva, focusing on proteases and protease inhibitors, their biological roles, and their potential in vaccines and therapies.
Jiří, Černý, Gunjan, Arora
openaire   +2 more sources

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

Expert Opinion on Investigational Drugs, 2003
Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. Complex metabolism by the cytochrome P450 system (particularly the 3A4 isoenzyme), action of membrane drug transporter elements (such as P-glycoprotein and ...
openaire   +2 more sources

Synthesis of New Thienyl Ring Containing HIV-1 Protease Inhibitors: Promising Preliminary Pharmacological Evaluation against Recombinant HIV-1 Proteases

Journal of Medicinal Chemistry, 2010
A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated.
Carlo Bonini, Lucia Chiummiento, Margherita De Bonis, Nadia Di Blasio, Maria Funicello, Paolo Lupattelli, Rocco Pandolfo, Francesco Tramutola, BERTI, FEDERICO   +8 more
openaire   +4 more sources

Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis

Journal of Gastroenterology, 2013
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is the most frequent complication of ERCP. Several meta-analyses have examined the effects of protease inhibitors (gabexate mesilate, ulinastatin, and nafamostat mesilate) and non-steroidal anti-inflammatory drugs (NSAIDs) on post-ERCP pancreatitis, but the results have been ...
Hiroki, Yuhara, Masami, Ogawa, Yoshiaki, Kawaguchi, Muneki, Igarashi, Tooru, Shimosegawa, Tetsuya, Mine   +5 more
openaire   +2 more sources

Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
We evaluated the feasibility and effectiveness of therapeutic drug monitoring (TDM) and adherence support (collectively, AT) vs standard of care (SOC) in patients receiving HIV protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) within a nurse-led clinic. Primary end points were failure to achieve viral load of
Khoo, Saye H., Lloyd, Judith, Dalton, Mark, Bonington, Alec, Hart, Elizabeth, Gibbons, Sara, Flegg, Peter, Sweeney, John, Wilkins, Edmund G L, Back, David J.   +9 more
openaire   +3 more sources

[Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001
Amprenavir is a novel protease inhibitor with antiviral activity, and was approved in the U.S. (AGEN-ERASE) in 1999 for use in combination with other antiretrovirals for the treatment of HIV infection. The drug is developed by Kissei Pharmaceuticals Co., Ltd. in Japan, approved in the same year, and has been distributed by them (PROZEI).
M, Ishizawa, H, Komatsu
openaire   +1 more source

Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions

Clinical Pharmacokinetics, 2015
Boceprevir is a potent, orally administered ketoamide inhibitor that targets the active site of the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to peginterferon plus ribavirin resulted in higher rates of sustained virologic response (SVR) than for peginterferon plus ribavirin alone in phase III studies in both ...
Sauzanne, Khalilieh, Hwa-Ping, Feng, Ellen G J, Hulskotte, Larissa A, Wenning, Joan R, Butterton   +4 more
openaire   +2 more sources